Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 6,000 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 824,106 shares in the company, valued at $41,205,300. This trade represents a 0.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tarsus Pharmaceuticals Trading Down 0.6 %

Shares of NASDAQ TARS traded down $0.32 during trading on Wednesday, reaching $51.01. The company had a trading volume of 291,655 shares, compared to its average volume of 641,617. The company’s fifty day moving average price is $48.73 and its 200-day moving average price is $45.78. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The stock has a market cap of $1.96 billion, a P/E ratio of -13.39 and a beta of 1.05. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $44,000. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $53,000. FMR LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth $166,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TARS. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Barclays cut their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, Guggenheim restated a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.